These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 19081418

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
    Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am J Cardiol; 2009 Feb 15; 103(4):515-22. PubMed ID: 19195513
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 Feb 15; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.
    Am J Cardiol; 2008 Feb 15; 101(4):486-9. PubMed ID: 18312763
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
    Yang LP, Keating GM.
    Am J Cardiovasc Drugs; 2009 Feb 15; 9(6):401-9. PubMed ID: 19929038
    [Abstract] [Full Text] [Related]

  • 9. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov 15; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.
    Jones PH, Davidson MH, Goldberg AC, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Lele A, Sleep DJ, Stolzenbach JC.
    J Clin Lipidol; 2009 Apr 15; 3(2):125-37. PubMed ID: 21291802
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Atherosclerosis; 2009 May 15; 204(1):208-15. PubMed ID: 18996523
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
    Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH.
    Am J Cardiol; 2008 May 15; 101(10):1428-36. PubMed ID: 18471454
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J.
    Am J Cardiol; 2005 Feb 15; 95(4):462-8. PubMed ID: 15695129
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug 15; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Am J Cardiol; 2010 Sep 15; 106(6):787-92. PubMed ID: 20816118
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul 15; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 19. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y.
    Curr Med Res Opin; 2006 May 15; 22(5):823-35. PubMed ID: 16709304
    [Abstract] [Full Text] [Related]

  • 20. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.